Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Organon & Co.

< Previous 1 2 Next >
First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Second Quarter Ended June 30, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
From Organon & Co.
Via Business Wire
Tickers OGN
Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the First Quarter Ended March 31, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report First Quarter and Host Conference Call on May 4, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the Piper Sandler 34th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Third Quarter Ended September 30, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Second Quarter Ended June 30, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
From Organon & Co.
Via Business Wire
Tickers OGN
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the First Quarter Ended March 31, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
From Organon & Co.
Via Business Wire
Tickers DARE OGN
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Declares Paid Time Off for All Employees on International Women’s Day; Employees to Focus on Their Own Health in Recognition of Growing Women’s Health Inequity
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.